Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study

Table 1 Patient demographics and baseline clinical characteristics

Characteristic	Secukinumab 150 mg (N = 116)	Secukinumab 150 mg no load (N = 117)	Placebo (N = 117)
Age (years), mean ± SD	44.5 ± 11.62	41.2 ± 11.07	43.4 ± 12.46
Male, n (%)	81 (69.8)	83 (70.9)	76 (65.0)
Caucasian, n (%)	113 (97.4)	117 (100)	114 (97.4)
Weight (kg), mean ± SD	83.4 ± 20.35	80.3 ± 18.23	80.6 ± 17.10
Time since AS diagnosis (years), mean ± SD	8.4 ± 10.84	6.5 ± 7.55	7.1 ± 9.23
HLA-B27 positive at baseline, n (%)	100 (86.2)	99 (84.6)	93 (79.5)
TNFi-naïve, n (%)	85 (73.3)	85 (72.6)	83 (70.9)
Total BASDAI score, mean ± SD	7.0 ± 1.23	6.95 ± 1.31	7.1 ± 1.27
hsCRP (mg/l), median (min–max)	6.25 (0.4–123.0)	6.20 (0.3–120.9)	5.40 (0.3–129.3)
Total back pain score (0–100 mm scale), mean ± SD	74.9 ± 13.07	74.2 ± 14.18	75.0 ± 13.80
Previous systemic treatment, n (%)
Methotrexate use at randomization	11 (9.5)	11 (9.4)	10 (8.5)
Sulfasalazine use at randomization	16 (13.8)	16 (13.7)	27 (23.1)
Corticosteroid use at randomization	11 (9.5)	10 (8.5)	13 (11.1)
Cumulative NSAID score, mean ± SD	64.0 (46.10)	68.3 (46.20)	60.4 (51.25)
Medical history, n (%)
Uveitis	23 (19.8)	21 (17.9)	27 (23.1)
Inflammatory bowel disease	2 (1.7)	4 (3.4)	0

AS ankylosing spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, hsCRP high-sensitivity C-reactive protein, HLA human leukocyte antigen, N number of patients randomized, n number of responders, NSAID non-steroidal anti-inflammatory drugs, s.c. subcutaneous, SD standard deviation, TNFi tumor necrosis factor-alpha inhibitors